Nanobody-Powered CAR-Ts take on tough lymphoma
NCT ID NCT07546630
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new type of CAR-T cell therapy that uses tiny antibodies (nanobodies) to target two markers on cancer cells (CD19 and CD20). The goal is to see if it is safe and to find the best dose for people with B-cell lymphoma that has come back or not responded to other treatments. About 20 participants will receive the therapy and be monitored for side effects and tumor response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could an AI-Designed pill take on Hard-to-Treat cancers?
- Engineered immune cells take aim at tough childhood cancers
- Experimental 'Off-the-Shelf' CAR-T therapy takes on tough lymphoma
- Promising CAR-T trial for blood cancer withdrawn before starting
- New hope for tough lymphomas: experimental drug STP938 enters human trials
- New CAR-T therapy takes aim at tough lymphoma cancers